New treatment to improve cord blood engraftment in children with leukemia after transplant
A Novel Post-transplant Regimen of PT/FLU+CY for Selectively Promoting Unrelated Cord Blood Engraftment in Haploidentical-cord Transplantation in Childhood Leukemia: a Single-arm, Multi-center Trial
This study is testing a new treatment to see if it can help children with leukemia have better success with cord blood transplants after their treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 1 Month to 18 Years |
| Sex | All |
| Sponsor | Nanfang Hospital, Southern Medical University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06155188 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate a novel post-transplant regimen of PT/FLU+CY to enhance the engraftment of unrelated cord blood in children undergoing hematopoietic stem cell transplantation (HSCT) for leukemia. The study focuses on the unpredictable nature of graft engraftment in haploidentical cord blood transplants and seeks to determine if this new approach can improve outcomes. By utilizing a combination of medications, the trial hopes to promote better integration of the cord blood grafts, potentially leading to improved patient recovery and survival rates.
Who should consider this trial
Good fit: Ideal candidates for this study are children diagnosed with acute leukemia who are undergoing hematopoietic stem cell transplantation.
Not a fit: Patients with multiple organ dysfunction syndrome (MODS) may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the success rates of cord blood engraftment in children with leukemia, leading to better treatment outcomes.
How similar studies have performed: While the approach of using PT/FLU+CY in this specific context is novel, similar strategies in haploidentical transplants have shown promise in other studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * children acute leukemia Exclusion Criteria: * MODS
Where this trial is running
Guangzhou, Guangdong
- Nanfang Hospital — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Xiaoqin Feng, MD — Department of Pediatrics, Nanfang Hospital, Southern Medical University
- Study coordinator: Yongsheng Ruan, MD
- Email: vimmer@smu.edu.cn
- Phone: 02062787966
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.